

Reference Number: FOI202122441
From: Commercial
Date: 20 January 2022
Subject: Prescribing

Q1 How many patients has your trust treated in the past 6 months (for any disease) with the following drugs:

- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaferon (interferon beta-1b)
- Brabio (glatiramer acetate)
- Copaxone (glatiramer acetate)
- Extavia (beta interferon-1b)
- Fampyra (fampridine)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Kesimpta (ofatumumab)
- Mavenclad (cladribine)
- Mayzent (siponimod)
- Ocrevus (ocrelizumab)
- Plegridy (peginterferon beta-1a)
- Rebif (beta interferon-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri - any formulation (natalizumab)
- Tysabri - pre-filled syringe ONLY (natalizumab)
- Zeposia (ozanimod)

A1

Drug Name	Number of Patients treated in the past 6 months
Aubagio (teriflunomide)	0
Avonex (interferon beta-1a)	1
Betaferon (interferon beta-1b)	0
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	0
Extavia (beta interferon-1b)	0
Fampyra (fampridine)	0
Gilenya (fingolimod)	0
Lemtrada (alemtuzumab)	0
Kesimpta (ofatumumab)	0
Mavenclad (cladribine)	0
Mayzent (siponimod)	0
Ocrevus (ocrelizumab)	0
Plegridy (peginterferon beta-1a)	0
Rebif (beta interferon-1a)	2

Tecfidera (dimethyl fumarate)	0
Tysabri - any formulation (natalizumab)	0
Tysabri - pre-filled syringe ONLY (natalizumab)	0
Zeposia (ozanimod)	0